faustor Profile Banner
Fausto A. Rios Olais Profile
Fausto A. Rios Olais

@faustor

Followers
1K
Following
3K
Statuses
32K

Culichi 🇲🇽 / Internal Medicine @incmnszmx / Hematology fellow @HemOncINCMNSZ / Interested in leukemia, clinical research & clinical reasoning

Distrito Federal, México
Joined July 2009
Don't wanna be here? Send us removal request.
@faustor
Fausto A. Rios Olais
16 hours
RT @RobertaDemiche3: 🔬 ¡Lanzamos un nuevo proyecto de leucemia linfoblástica aguda (LLA)! 🌎💉 Si tratas adultos con LLA en LATAM, te invitam…
0
14
0
@faustor
Fausto A. Rios Olais
6 days
@carmencrios Ando igual 🆘🆘🆘🆘
0
0
0
@faustor
Fausto A. Rios Olais
9 days
RT @incmnszmx: El INCMNSZ felicita a la Dra. María Roberta Demichelis Gómez por su nombramiento como Jefa del Departamento de Hematología y…
0
42
0
@faustor
Fausto A. Rios Olais
1 month
RT @JessicaZaS: 1/ 📢 Let’s dive into a crucial topic in #Hematology: How do adult regimens compare with pediatric-inspired regimens (PIRs)…
0
6
0
@faustor
Fausto A. Rios Olais
2 months
7/ Conclusions 🔹 Rituximab + TKIs may improve early responses and enhance survival in CD20+ Ph+ ALL without added toxicity. 🔹 These findings are critical for LMICs, where access to newer therapies is limited. 🔹 Future prospective trials are essential to confirm these results.
1
0
2
@faustor
Fausto A. Rios Olais
2 months
Primary focus: ✔️ Molecular remission (MR4) at 3 months. ✔️ Secondary: Overall survival (OS), event-free survival (EFS), safety, and dose-response effects of rituximab.
0
0
0
@faustor
Fausto A. Rios Olais
2 months
1/ Rituximab in ALL: What we know For Ph-neg B-ALL, rituximab has shown clear benefits: 🩺 Improved EFS (in trials like GRAALL-2005) 🩺 Enhanced outcomes, esp with ≥8 doses But for Ph-pos B-ALL evidence is lacking, as most trials exclude these patients
1
13
38
@faustor
Fausto A. Rios Olais
2 months
RT @ALL_Hub_: CONGRESS | #ASH24 | POSTER Fausto A Rios-Olais @faustor @incmnszmx shares findings from a study examining the relationship b…
0
2
0
@faustor
Fausto A. Rios Olais
2 months
So now that we’re certain that “blin’s-for-all”, efforts should be made to assure its access in resource-limited settings
Tweet media one
0
3
18
@faustor
Fausto A. Rios Olais
2 months
RT @GomezDLeonMD: The Mexican contingent at #ASH24 Fellows from INCMNSZ (Mexico city) HU UANL (Monterrey)… and two young-looking albeit w…
0
7
0
@faustor
Fausto A. Rios Olais
2 months
Got great news to start #ASH24 that I got accepted into @ASH_hematology Advanced CRTI-LA. See you next year in Punta del Este 🇺🇾 thanks to my mentor @RobertaDemiche3! 🫰🏻🩸
Tweet media one
5
0
46
@faustor
Fausto A. Rios Olais
2 months
@RobertaDemiche3 @INCMNSZ_Ensena @HemOncINCMNSZ Producto del trabajo en equipo en la clínica de leucemias agudas! 😃😃 @rajuan_27 @analymorac @JuanLmd @IvanArnaud @JonahSerranoMD
1
0
5
@faustor
Fausto A. Rios Olais
2 months
RT @ALL_Hub_: 🚨 #ASH24 is nearly here! The list of top abstracts selected by the ALL Hub Steering Committee for the 66th ASH Annual Meeti…
0
5
0
@faustor
Fausto A. Rios Olais
4 months
0
0
1
@faustor
Fausto A. Rios Olais
5 months
One of my best friends is applying for IM #Match2025. Great human being and excellent physician. Any program would be lucky to have him on their team 🙌🏻
@FernandoGLMD
Fernando Gil-Lopez
5 months
Hi #MedX #MedTwitter, I'm Fernando Gil-Lopez, an IMG and internist from 🇲🇽 applying for #IM #Match2025. I am passionate about #MedEd, academia, history, sports and cinema. Very excited to continue growing in Internal Medicine and connect with programs and fellow applicants!
Tweet media one
0
1
18